Clinical Trials Logo

Scleroderma clinical trials

View clinical trials related to Scleroderma.

Filter by:

NCT ID: NCT03141125 Completed - Scleroderma Clinical Trials

The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy

Start date: January 2016
Phase: N/A
Study type: Interventional

Study about the effect of ethanol extract physalis angulate in scleroderma patients with standard therapy to reduce skin fibrosis based on modified Rodnan Skin Score, reduce inflammation, immunological response and fibrosis: A Randomized Clinical Placebo ControlledTrial with a prospective cohort study on scleroderma outpatient clinic in Cipto Mangunkusumo Hospital in Jakarta and Hasan Sadikin Hospital in Bandung, from January 2016 to July 2017

NCT ID: NCT03092024 Completed - Systemic Sclerosis Clinical Trials

Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study

SPIN-HAND-F
Start date: June 1, 2017
Phase: N/A
Study type: Interventional

The Scleroderma Patient-centered Intervention Network (SPIN) is an organization established by researchers, health care providers, and people living with scleroderma from Canada, the USA, and Europe. The objectives of SPIN are (1) to assemble a large cohort of scleroderma patients to complete outcome assessments regularly in order to learn more about important problems faced by people living with scleroderma and (2) to develop and test a series of internet-based interventions to help patients manage aspects of scleroderma, including hand limitations. In the SPIN-HAND feasibility trial, SPIN Cohort participants with at least mild hand function limitations and an indicated interest in using an online hand exercise program will be randomized to be offered the SPIN hand exercise program or to usual care only. The core SPIN hand exercise program consists of 4 modules that address specific aspects of hand function, including Thumb Flexibility and Strength; Finger Bending; Finger Extension; and Wrist Flexibility and Strength. The program also integrates tools to support key components of successful self-management programs, including goal-setting. The aim of the SPIN-HAND feasibility study is to collect data to assess the feasibility of the steps that need to take place as part of the main trial; required resources; and scientific aspects (e.g., withdrawal rate, outcomes measures). Data will be used to determine whether it is feasible to carry out the main study or whether changes need to be made before conducting a full-scale RCT of the SPIN-HAND program.

NCT ID: NCT02915835 Completed - Scleroderma Clinical Trials

Riociguat in Scleroderma Associated Digital Ulcers

RESCUE
Start date: September 2016
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with scleroderma-associated digital ulcers

NCT ID: NCT02896205 Completed - Systemic Sclerosis Clinical Trials

Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease

MYILD
Start date: October 2016
Phase: Phase 3
Study type: Interventional

Systemic sclerosis is a multisystem disease and can involve the lungs in the form of ILD. Lung involvement is the most common cause of death in these patients. The present study is performed to study the efficacy of oral mycophenolate mofetil in treating early and mild ILD in patients of SSc. The efficacy and side effects of mycophenolate mofetil will be compared with that of oral placebo.

NCT ID: NCT02887495 Completed - Scleroderma Clinical Trials

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

Start date: July 2014
Phase:
Study type: Observational

The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.

NCT ID: NCT02837549 Completed - Scleroderma Clinical Trials

Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma

Start date: July 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the feasibility and preliminary effects of a novel treatment approach to improve arm function in patients with scleroderma who have upper extremity contractures. It is a Phase 1, one arm trial in which participants will be assessed at baseline, 4 weeks, and 8 weeks. The rehabilitation intervention will involve 8 individual sessions with an occupational therapist. Feasibility of the procedures is a major focus of this project.

NCT ID: NCT02835196 Completed - Scleroderma Clinical Trials

Optical Elastography of Systemic Sclerosis Skin

Start date: October 25, 2017
Phase:
Study type: Observational

The goal of this study is to develop a new way to assess skin thickness in patients with scleroderma (systemic sclerosis). The study will test how well a new imaging method called optical coherence elastography (OCE) compares to the current clinical method used to estimate skin thickness, the modified Rodnan Skin Score (mRSS).

NCT ID: NCT02798055 Completed - Scleroderma Clinical Trials

Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis

GRegistry SCDU
Start date: September 30, 2016
Phase:
Study type: Observational [Patient Registry]

GRegistry is a significant collection of data and information on the clinical practice of systemic scleroderma finger ulcers. The GRegistry study is a nationwide (Greece) prospective study recording, which includes consecutive patients with SC-DU diagnosis in clinical management departments of different hospitals, selected in such a way as to reflect a representation of the country. The use of Bosentan in the treatment of patients suffering from systemic sclerosis with digital ulcer disease is supported by data from large, placebo-controlled, randomized studies. The beneficial effect of Bosentan in digital ulcers, a vascular event of systemic sclerosis consistent with its beneficial effect on pulmonary arterial hypertension associated with connective tissue disease and its beneficial effect on vascular remodeling.

NCT ID: NCT02733978 Completed - Scleroderma Clinical Trials

Ozone Therapy in the Treatment of Digital Ulcers in Patients With Systemic Sclerosis

Start date: June 2016
Phase: N/A
Study type: Interventional

Digital ulcers (DUs) in scleroderma result from recurrent Raynaud's phenomenon (RP) and microtrauma with high impact on quality of life, management of DUs is a great challenge for clinicians. Medical use of ozone (triatomic oxygen) was initiated in the 19th century. Ozone has multiple therapeutic effects in wound healing due to the property of releasing nascent oxygen, which has been shown to stimulate antioxidant enzymes.

NCT ID: NCT02610842 Completed - Scleroderma Clinical Trials

Hands on - a Hand Care Guide in Systemic Sclerosis

Start date: January 2015
Phase: N/A
Study type: Interventional

Hands are commonly affected in Systemic Sclerosis (SS). The objective of this research is to apply a home based hand care guide in patients with SS and to evaluate its response regarding hand pain, function, strength and mobility.